Hydroxyurea is a inhibitor of DNA synthesis in vivo, and an antiviral and antineoplastic agent which is S-phase specific. A ribonucleotide reductase inhibitor - inhibits by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. Induces fetal hemoglobin production in sickle cell anemia patients.
Hydroxyurea induces apoptosis of in vitro myelogenous leukemia lymphocytes, and the phosphorylation of FADD and p53. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.
Anti-neoplastic. Inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronization or cell death in S-phase.
Key Applications: Cancer Research, Apoptosis and Cell Cycle
Application Areas: Molecular biology and Cell biology
Product Type: Biochemicals
Biochemical Category: Biochemicals
Melting Point: 136 - 146°C
Presentation: White Crystalline Powder
Format: Crystalline Powder
Solubility: Freely soluble in water (50 mg/mL-clear colorless solution) or hot alcohol.
Storage & Handling: Store at +4°C.